SCHEMBL1700835

SCHEMBL1700835

O=C(C(F)(F)Oc1ccccc1)C(F)(F)Oc1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SSTR4 P31391 3/20 0.43
SSTR1 P30872 1/20 0.42
CES1 P23141 2/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC2 Q92769 1/20 0.41
ALOX15 P16050 1/20 0.40
GAA P10253 1/20 0.40
SERPINE1 P05121 1/20 0.39
MAOB P27338 1/20 0.39
EPHX2 P34913 2/20 0.38
ALDH1A1 P00352 1/20 0.38
TSHR P16473 1/20 0.38
HSD17B10 Q99714 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2C19 P33261 1/20 0.38
LTA4H P09960 1/20 0.38
MAPK14 Q16539 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8827475 0.91 CES1 (0.43) SSTR4SSTR1CES1HDAC1HDAC2
SCHEMBL17674534 0.86 SSTR4 (0.43) SSTR4SSTR1CES1HDAC1HDAC2
SCHEMBL1557506 0.83 SSTR4 (0.41) SSTR4SSTR1CES1HDAC1HDAC2
SCHEMBL1170319 0.83 PARP10 (0.42) SSTR4SSTR1CES1HDAC1HDAC2
SCHEMBL1170317 0.83 SSTR4 (0.41) SSTR4SSTR1CES1HDAC1HDAC2
SCHEMBL25353899 0.81 SSTR4 (0.40) SSTR4SSTR1CES1HDAC1HDAC2
SCHEMBL17491573 0.79 SSTR4 (0.38) SSTR4SSTR1CES1HDAC1HDAC2
SCHEMBL20387981 0.78 SSTR4 (0.50) SSTR4SSTR1EPHX2CYP1A2CYP2C19
SCHEMBL27976153 0.77 EPHX2 (0.52) HDAC1HDAC2SERPINE1EPHX2CYP1A2
Acetic Acid SCHEMBL29103732 0.76 EPHX2 (0.50) HDAC1HDAC2SERPINE1EPHX2CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240115649-A1 CASPASE INHIBITION TO ENHANCE REGENERATION AND REPAIR AFTER SKIN OR GUT INJURY AND TO TREAT BACTERIAL OR VIRAL INFECTIONS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2024-04-11 US claimed
EP-4531919-A1 METHOD OF TREATING VITILIGO WITH INTERFERON-GAMMA ANTIBODY Elixiron Immunotherapeutics (Hong Kong) Limited (HK) 2025-04-09 EP disclosed
WO-2023235830-A1 METHOD OF TREATING VITILIGO WITH INTERFERON-GAMMA ANTIBODY ELIXIRON IMMUNOTHERAPEUTICS (HONG KONG) (CN) 2023-12-07 WO disclosed
EP-3049530-B1 METHOD FOR CELL-FREE PROTEIN SYNTHESIS IN THE PRESENCE OF A CASPASE INHIBITOR FRAUNHOFER GES FORSCHUNG (DE) 2022-06-22 EP disclosed
CN-109072193-A The composition and method of B cell genome editor 达纳-法伯癌症研究所有限公司 2018-12-21 CN disclosed
US-9951366-B2 Cell-free protein synthesis method and device using a eukaryotic cell lysate in the presence of a caspase inhibitor and the use of a caspase inhibitor for increasing the yield and/or the stability of the synthesized proteins in such a method FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E. V. (DE) 2018-04-24 US disclosed
CN-106232106-A Particulate vaccine formulations for inducing innate and adaptive immunity 奥本大学 2016-12-14 CN disclosed
US-20160251692-A1 CELL-FREE PROTEIN SYNTHESIS METHOD AND DEVICE USING A EUKARYOTIC CELL LYSATE IN THE PRESENCE OF A CASPASE INHIBITOR AND THE USE OF A CASPASE INHIBITOR FOR INCREASING THE YIELD AND/OR THE STABILITY OF THE SYNTHESIZED PROTEINS IN SUCH A METHOD FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E. V. (DE) 2016-09-01 US disclosed
WO-2011137485-A1 MEDIA AND METHODS FOR CELL CULTURE SYDNEY IVF LIMITED (AU) 2011-11-10 WO disclosed
EP-0840614-A1 CALPAIN INHIBITORS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES SANOFI WINTHROP, INC. (US) 1998-05-13 EP disclosed
WO-1996041638-A1 CALPAIN INHIBITORS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES SANOFI WINTHROP, INC. (US) 1996-12-27 WO disclosed